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Double-stranded RNAs 21 nucleotides long [small interfering
RNA (siRNA)] are recognized as powerful reagents to reduce the
expression of specific genes. To use them as reagents to protect
cells against viral infection, effective methods for introducing
siRNAs into primary cells are required. Here, we describe success in
constructing a lentivirus-based vector to introduce siRNAs against
the HIV-1 coreceptor, CCR5, into human peripheral blood T lym-
phocytes. With high-titer vector stocks, >40% of the peripheral
blood T lymphocytes could be transduced, and the expression of a
potent CCR5-siRNA resulted in up to 10-fold inhibition of CCR5
expression on the cell surface over a period of 2 weeks in the
absence of selection. In contrast, the expression of another major
HIV-1 coreceptor, CXCR4, was not affected. Importantly, blocking
CCR5 expression by siRNAs provided a substantial protection for
the lymphocyte populations from CCR5-tropic HIV-1 virus infection,
dropping infected cells by 3- to 7-fold; only a minimal effect on
infection by a CXCR4-tropic virus was observed. Thus, our studies
demonstrate the feasibility and potential of lentiviral vector-
mediated delivery of siRNAs as a general means of intracellular
immunization for the treatment of HIV-1 and other viral diseases.
A lthough the idea of protecting cells against HIV-1 infectionby the internal production of a protective molecule (‘‘in-
tracellular immunization’’) was suggested 14 years ago (1), it has
not been realized as a clinical procedure, partly because no
macromolecule has proved potent enough and because of lim-
itations in gene delivery vehicles. Recently, it has been appre-
ciated that small, double-stranded RNAs (siRNA) can be pow-
erful sequence-specific catalysts for targeted RNA destruction
by means of an evolutionarily conserved mechanism known as
RNA interference (RNAi) (2–5). The properties of siRNA
suggest its potential as an ‘‘intracellular immunogen.’’ With the
discovery that siRNAs can be effectively produced as hairpin
transcripts from RNA polymerase III (Pol III) promoters (6–
11), intracellular synthesis of siRNAs has become feasible. The
best vector for delivering an siRNA template would be a
lentivirus vector derived from HIV-1, because such vectors
stably infect nondividing cells and are not subject to the silencing
imposed on other retrovirus vectors (a ‘‘turning the tables’’
approach; refs. 12 and 13). Furthermore, lentiviral vectors have
proven to be effective in expressing transgenes within multiple
lineages over prolonged periods of time and safe in SCID-hu and
non-human primate hematopoietic stem cell transplants (14, 15).
HIV-1 infection could be prevented by either an siRNA directed
against viral RNA, as has been done in several in vitro models
(16–20), or by targeting the mRNA for the primary HIV-1
coreceptor, CCR5. CCR5 suggests itself as a target because
people who lack both genes for CCR5 (CCR532 homozygotes)
are resistant to HIV-1 infection but are otherwise apparently
normal (21–24). We report here the successful use of this
approach.
Materials and Methods
Vector Construction. A human U6-RNA pol III promoter (328 to
1) was amplified from HEK-293 genomic DNA with primers
5-gggaattcccccagtggaaagacgcgcag-3 and 5-cggaagcttgaagaccacg-
gtgtttcgtcctttccacaa-3, in which a BbsI site was introduced at the 3
end allowing the insertion of siRNA sequences at the 1 position
of the U6 transcript. The PCR fragment was cloned at EcoRI–
HindIII sites of pBS-SKII plasmid (Stratagene). Sequencing anal-
ysis showed all of the individual clones recovered had a GCGCG
insertion at the 267 position comparing to the published human
U6-RNA promoter sequence (GenBank accession nos. X07425 and
M14486). This difference might originate either from a PCR error
or a natural polymorphism. Nevertheless, transient transfection
assays showed that this promoter fragment was fully functional
(X.-F.Q. and D.B., unpublished data). To construct the hairpin
siRNA expression cassette, two complementary DNA oligos (see
below) were synthesized, annealed, and inserted between BbsI and
XhoI sites immediately downstream of the U6 promoter: 5- acc-
g(n)18ttcaagaga(n)18ctttttc-3; 3-(n)18aagttctct(n)18gaaaaagagct-
5. The 19-nt sense and reverse complementary targeting sequences
are highlighted in bold. Note that the sense targeting sequence
always starts with G at position 1 (thus, the reverse complementary
sequence ends with C), as required for the efficient transcription
initiation from the U6 promoter (25). The siRNA cassette also
features a TTCAAGAGA loop situated between the sense and
reverse complementary targeting sequences and a TTTTT termi-
nator at the 3 end. The CCR5-siRNA (186) contains the sense
targeting sequence of gagcatgactgacatctac corresponding to the
186–204 nucleotide positions of human CCR5 coding sequence
(GenBank accession no. U57840), whereas the CCR5-siRNA (809)
has the targeting sequence of gtagctctaacaggttgga to the 809–827
nucleotide positions. The targeting sequence for lacZ-siRNA is
gtgaccagcgaatacctgt, which is directed to the 1915–1933 region of
the bacterial galactosidase gene.
FG12 lentiviral vector was derived from FUGW (26). The
extra nucleotides from the HindIII site downstream of the
Ubiquitin-C promoter (UbiC) promoter to the NcoI site in front
of the initiation codon of GFP were deleted by a HindIII–NcoI
adapter ligation. Further, XbaI, EcoRI, and XhoI sites at the 3
end of GFP and WRE were eliminated, followed by a polylinker
oligonucleotide ligation at the PacI site between the Flap
element and the UbiC promoter, to generate a set of new
restriction sites, XbaI–HpaI–XhoI–BstXI–PacI, that is optimal
for accommodating the siRNA expression cassette (X.-F.Q. and
D.B., unpublished data). To construct the siRNA-expressing
lentiviral vectors, the siRNA expression cassette was subcloned
into FG12 between the XbaI and XhoI sites. The resulting
plasmid was confirmed by restriction enzyme digestion and DNA
sequencing.
Abbreviations: siRNA, small interfering RNA; PBLs, peripheral blood lymphocytes; FACS,
fluorescence-activated cell sorter; HSA, murine heat-stable antigen; UbiC, Ubiquitin-C
promoter.
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Lentiviral Vector Production. All vesicular stomatitis virus (VSV)-
G pseudotyped lentiviral vector stocks were produced by calcium
phosphate-mediated transient transfection of HEK-293 T cells.
Briefly, HEK-293 T cells were cultured in either Iscov’s modified
Eagle’s medium or DMEM (GIBCO Invitrogen) containing
10% FCS (HyClone), 100 units of penicillin, and 100 gml
streptomycin. The cells were cotransfected with appropriate
amounts of vector plasmid, the HIV-1 lentiviral packaging
constructs pRSVREV (27) and pMDLgpRRE (27), and the
VSV-G expression plasmid pHCMVG (28). The viruses were
collected from the culture supernatants on days 2 and 3 post-
transfection and concentrated 100- to 1,000-fold by ultracentrif-
ugation (28). The concentrated virus stocks were titered on
HEK-293 T cells based on GFP expression. Titers for the siRNA
expression constructs were only slightly reduced compared with
the parental vector.
Cell Culture and Lentiviral Vector Transduction. Magi-CCR5 cells
(29) (AIDS Research and Reference Reagent Program of the
National Institutes of Health) were maintained in DMEM, 10%
FCS containing 200 g of G418 (GIBCOBRL), 100 g of
hygromycin, and 1 gml puromycin (Sigma). The stable ex-
pression of human CD4 and CCR5 on the cell surface was
confirmed by fluorescence-activated cell sorter (FACS) analysis.
The cells were transduced with concentrated lentiviral vector
stocks at a multiplicity of infection (moi) of 10–25 (note that
Magi-CCR5 cells have a considerable lower transducing effi-
ciency) in the presence of 8 gml polybrene (Sigma). The
transduced cells were harvested 4 days later and stained with
Cy-Chrome-labeled mouse anti-human CCR5 mAb (2D7,
PharMingen) or a mouse IgG2ak isotype control (OX-35,
PharMingen), according to the manufacturer’s instructions.
Human peripheral blood lymphocytes (PBLs) were isolated
from leukopacks by Histopaque (Sigma) and cultured in RPMI
medium 164020% FCS with 2.5 g of phytohemagglutinin
(PHA) (Murex Biotech, Dartford, U.K.)100 units of penicillin
100 g/ml streptomycin for 2 days. After 2 days of PHA
stimulation, CD8 cells were depleted by M450 CD8 Dynabeads
(Dynal, Great Neck, NY) and the residual amount of CD8 cells
was 1%, as confirmed by FACS analysis. The CD8-depleted
PBLs were used for lentiviral vector transduction. Briefly, 4 
105 cells were incubated with various lentiviral vectors at a moi
of 5 for 2 h in the presence of 8 gml polybrene. After the
incubation, virus supernatants were removed and replaced with
1.5 ml of fresh RPMI medium 164020% FCS containing 20
unitsml IL-2 (Roche Molecular Biochemicals). GFP, CD4,
CCR5, and CXCR4 expression was analyzed by FACS at mul-
tiple time points after transduction. Note that, although a moi of
5 was used for transduction with different lentivectors, actual
transduction efficiency appeared to vary from sample to sample,
depending on the initial titers of the virus preparations.
HIV-1 Virus Production and Infection. Stocks for the murine heat-
stable antigen (HSA)-expressing HIV-1 reporter viruses,
NFNSX-r-HSAS (CCR5-tropic; ref. 30) and NL-r-HSAS
(CXCR4-tropic; ref. 31), were produced by calcium phosphate
transfection with the infectious proviral plasmid in HEK-293 T
cells. The virus supernatants were filtered with 0.22-m filters
and stored at70°C. The p24 value of the virus stocks was 6,966
ngml for NFNSX-r-HSAS and 1,077 ngml for NL-r-HSAS.
Four days after lentivector or mock transduction, the PBLs (5
105 cells) were infected with 100 l of NFNSX-r-HSAS or
NL-r-HSAS virus in the presence of 8 gml polybrene for 2 h.
After the incubation, the cells were washed and replated with 1.5
ml of RPMI medium 164020% FCS and 20 unitsml IL-2. The
rate of infection was determined by FACS analysis for HSA
expression on the cell surface at various times points as indi-
cated. p24 levels in the culture supernatants were measured by
ELISA.
FACS Analysis. Cells (5  105) were stained with monoclonal
antibodies to human CCR5 [2D7, allophycocyanin (APC)-
labeled, BD Biosciences], CXCR4 (CXCR4, APC-labeled, BD
Biosciences), and CD4 [RPAT4, phycoerythrin (PE)-labeled,
eBioscience], according to the manufacturer’s instructions. For
measuring HIV-1 reporter virus infection, a PE-labeled anti-
murine HSA mAb (M169, PharMingen) was used. The cells
were also stained with isotype controls for each of the specific
antibodies. The stained cells were fixed with 2% formaldehyde
and acquired on a FACScan or FACSCalibur (Becton Dickin-
son). The data analysis was performed with CELLQUEST (Becton
Dickinson) or FLOWJO (Tree Star, San Carlos, CA) software.
Results
The backbone of the siRNA expression vector was derived from
FUGW, an HIV-1-based lentivirus vector originally designed for
germ-line gene transduction (26). The short hairpin form of
siRNA template was transcribed from a human U6-RNA poly-
merase III (Pol III) promoter, and the expression cassette was
inserted in the forward orientation at the junction of the HIV-1
DNA Flap element (Flap) and UbiC of the vector FG12 (Fig.
Fig. 1. Construction of a lentivirus-based vector for delivering anti-human
CCR5 siRNAs. (A) Schematic diagram of the siRNA-expressing lentiviral vector.
The short hairpin form of siRNA is expressed under the control of a human
U6-RNA Pol III promoter (Pol III). The vector also contains a human UbiC
promoter driving the GFP marker gene for tracking transduced cells. 5 LTR,
HIV-1 5LTR; 3 LTR, HIV-1 self-inactivating 3LTR; Flap, HIV-1 DNA flap
element; WRE, woodchuck hepatitis B virus RNA regulatory element. (B)
Selection of siRNA constructs that can effectively inhibit CCR5 expression in
Magi-CCR5 cells. Magi-CCR5 cells were transduced with various lentiviral
vectors. The cells were harvested 4 days after virus transduction and analyzed
by FACS with anti-human CCR5 or isotype control antibody staining. The
productively transduced (GFP) and nontransduced (GFP) cells were gated
based on their GFP signals. The CCR5 staining is represented by the open curve
and the isotype control by the shaded curve. Note that some lower GFP-
expressing cells were included in the GFP gate and, thus, there appeared to
be a slight decrease of CCR5 staining in this population of the anti-CCR5
vector-transduced samples. CCR5-siRNA(186), the vector expressing a potent
anti-CCR5 siRNA; CCR5-siRNA(809), the vector expressing a weaker anti-CCR5
siRNA; lacZ-siRNA, a nonspecific siRNA vector; FG12, empty vector; Mock,
mock transduction control.
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1A). This configuration permits high-titer virus production and
the functional expression of siRNA templates in murine spleno-
cytes, bone marrow cells, and transgenic animals (X.-F.Q., C.
Lois, and D.B., unpublished data). The vector also expresses a
human UbiC-driven GFP gene to provide a marker for tracking
transduced cells (Fig. 1 A). To identify an effective siRNA
targeted to CCR5, we first used Magi-CCR5 cells (29) carrying
a transfected human CCR5 gene as a target. Mock-transduced
Magi-CCR5 cells expressed no GFP but had a high level of
CCR5 expression on the cell surface (Fig. 1B). Cells transduced
by a vector lacking the siRNA cassette (FG12) or a control
siRNA cassette against lacZ (lacZ-siRNA) contained many
GFP cells (positively transduced cells), but CCR5 expression
was unaltered in these cells (Fig. 1B). However, with an anti-
CCR5-specific siRNA-expressing vector targeting to the 809–
827 region of the human CCR5 mRNA coding sequence [CCR5-
siRNA (809)], the surface expression of CCR5 on the GFP
cells was dropped to 30–40% the level of the controls, judging
by the mean fluorescence intensity of CCR5 antibody staining
(Fig. 1B). More significantly, the anti-CCR5 siRNA construct
directed to the 186–204 region [CCR5-siRNA (186)] resulted in
90% reduction of CCR5 expression (Fig. 1B). In addition to
CCR5-siRNA (809) and CCR5-siRNA (186), we also tested
several other constructs targeting to different regions of CCR5
mRNA; these exhibited variable degrees of effectiveness but
none 90% inhibition (not shown). A systematic approach
might in the future identify even more potent siRNA templates,
but the 90% inhibition provided by the CCR5-siRNA (186)
vector appeared to be sufficient for our further studies described
below.
To test the efficacy of the vector against HIV-1 infection in
primary human CD4T cells, PBLs depleted of CD8 cells were
isolated, stimulated with phytohemagglutinin (PHA) for 2 days,
and transduced or mock transduced with various vectors. After
the transduction, the cells were cultured in the presence of
human IL-2. IL-2 elicits the synthesis and surface expression of
CCR5 as well as the other major HIV-1 coreceptor CXCR4 on
activated T cells (32, 33). We monitored CCR5 and CXCR4
expression levels at various time points by FACS. Fig. 2 shows
FACS plots from a representative experiment (Donor B) at day
8 post-vector transduction. Quantitative analyses of the FACS
results from two donors (A and B) are shown in Table 1, and
more extensive time course studies with four different donors
(A, B, C, and D) will be presented in Table 3. The mock-
transduced cells in Fig. 2 A showed that 30% of the cells were
CCR5. The cells transduced with the vector control (FG12)
had 60% GFP, and among those positively transduced cells,
there were still29% cells expressing CCR5 (Table 1, Donor B).
lacZ-siRNA-transduced cells had a similar percentage of CCR5
positivity (Table 1), but there were fewer GFP positive cells,
presumably because of a lower titer of the viral stock. Over 40%
of PBLs were productively transduced by the CCR5-siRNA
(186) vector, and within this GFP population only 3.4% of the
cells scored positive for CCR5 expression, suggesting that siRNA
expression caused an 10-fold reduction in CCR5 positivity
compared with a lacZ-siRNA control (Table 1). Of the remain-
ing CCR5-siRNA (186)-transduced cells that still expressed
CCR5, the mean fluorescence intensity as a measure of relative
abundance of CCR5 surface expression was substantially re-
duced. For the GFP population, levels of CCR5 expression
were slightly higher than in controls (Table 1), showing that
down-regulation of CCR5 expression only occurred in the
productively transduced cells. In contrast to CCR5, Fig. 2B and
Fig. 2. Reduction of CCR5 surface expression on human PBLs transduced by
anti-CCR5 lentiviral vector. PHA-stimulated and CD8-depleted PBLs were
transduced with various lentiviral vectors as described in Fig. 1. The transduced
cells were further cultured in IL-2-containing medium for 8 days before FACS
analysis for CCR5 or CXCR4 expression on the cell surface. A representative
experiment with Donor B is shown. (A) Cells were stained with allophycocya-
nin (APC)-labeled anti-human CCR5 mAb (2D7, PharMingen). The results are
exhibited as CCR5 vs. GFP dotplots with cell populations in the live lymphocyte
gate (typically75%). The quadrant lines were defined by mock-transduction
and isotype-control staining, and the percentage numbers are indicated. (B)
Cells were stained with APC-labeled anti-human CXCR4 mAb (CXCR4, Phar-
Mingen), and the results are plotted in the same manner as in A.
Table 1. Selective down-regulation of CCR5 expression by lentiviral vector-mediated delivery of anti-CCR5 siRNA in human PBLs
Donor Treatment*
CCR5 expression CXCR4 expression
% of CCR5 cells in
the GFP population†
% of CCR5 cells in
the GFP population†
Fold of
reduction‡
% of CXCR4 cells in
the GFP population†
% of CXCR4 cells in
the GFP population†
Fold of
reduction‡
A Mock 36.83 NA 37.43 NA
FG12 43.03 27.96 37.07 46.38
lacZ-siRNA 50.20 25.36 33.94 49.24
CCR5-siRNA 42.87 3.63 6.99 39.95 52.22 0.94
B Mock 30.30 NA 48.80 NA
FG12 41.62 29.00 39.68 47.09
lacZ-siRNA 35.48 32.63 45.44 47.64
CCR5-siRNA 49.16 3.38 9.65 31.27 51.30 0.93
NA, not applicable.
*Lentiviral vector transduction was performed as described in Fig. 2. Eight days after the transduction, the cells were analyzed by FACS for the surface expression
of CCR5 or CXCR4 (Materials and Methods).
†Calculated from the quadrant percentage numbers from the CCR5 or CXCR4 vs. GFP FACS plots shown in Fig. 2.
‡Expressed as the ratio of the percentage of CCR5 or CXCR4 cells scored in the GFP population between lacZ-siRNA and CCR5-siRNA [CCR5-siRNA(186)]-
transduced samples.
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the data in Table 1 show that CXCR4 expression was not
affected by the anti-CCR5 siRNA-expressing vector. Thus,
lentivector-mediated expression of an appropriate siRNA in
primary human T cells can specifically reduce the expression of
CCR5.
To examine the effect of blocking CCR5 expression by the
anti-CCR5 siRNA lentivector on HIV-1 infection, the lympho-
cyte populations were challenged with a CCR5-tropic HIV-1
reporter virus. This reporter virus is modified to express the
HSA marker in place of the HIV-1 accessory gene Vpr, which
allows the assay for HIV-1 infection at the single-cell level by
enumerating HSA cells (30). Table 2 shows the quantitative
results of FACS analysis with two different donor samples and
Fig. 3 shows representative FACS plots from Donor B. With the
empty vector (FG12) and the lacZ-siRNA vector (lacZ-siRNA),
8% and 11% of the GFP cells were infected by the virus, as
measured by the expression of the HSA marker (see Table 2 for
percentages). With the anti-CCR5 siRNA vector [CCR5-siRNA
(186)] treatment, only 1.7% of the GFP cells were detectably
positive for HIV-1 infection, Thus, for this donor, expression of
the specific siRNA led to a 6-fold drop in the level of cells
infected by a CCR5-tropic HIV-1 virus. A slightly lower level of
protection (3.64-fold) was also obtained from another donor
(Table 2, Donor A). More extensive time course experiments
with additional donors (Table 3) showed that effective CCR5
down-regulation and inhibition to CCR5-tropic HIV-1 infection
occurred with all of the donors over a period of 7–8 days,
although the degree of effectiveness varied from donor to donor
(within the range of 3- to 7-fold of protection). In addition to the
GFP-transduced cells, we found that the frequency of the
HIV-1-infected HSA cells in the GFP population was also
decreased 2- to 3-fold in comparison with the mock, empty
vector (FG12), and lacZ-siRNA controls (Fig. 3A; Table 2,
Donors A and B). Consistent with this observation, supernatant
p24 levels, a measurement of virus production, were reduced
3-fold (Fig. 4), despite the fact that cells without siRNA to
CCR5 outnumber the siRNA-transduced population. Thus, the
anti-CCR5 siRNA was not only effective at protecting the
transduced cells in a mixed population, but also resulted in an
overall reduction of virus load and decreased infection of
Fig. 3. Inhibition of CCR5-tropic HIV-1 infection in human PBLs transduced
by lentiviral vector expressing anti-CCR5 siRNA. PBLs were transduced by
various lentiviral vectors as described in Fig. 2. The transduced PBLs were
cultured in IL-2-containing medium for 4 days before being challenged with
either the CCR5-tropic reporter virus (A) or the CXCR4-tropic reporter virus (B).
The cells were harvested 4 days after the virus challenge, and the virus-
infected cells were quantitated by FACS analysis for the expression of the HSA
marker. The FACS results are presented as HSA vs. GFP dotplots with cell
populations in the live lymphocyte gate. The quadrant lines were defined by
mock-infection and isotype-control staining, and the percentage numbers are
indicated. One representative experiment with Donor B is shown.
Table 2. Inhibition of CCR5-tropic HIV-1 infection by lentiviral vector-mediated delivery of anti-CCR5 siRNA in human PBLs
Donor Treatment*
Response to CCR5-tropic HIV-1 challenge Response to CXCR4-tropic HIV-1 challenge
% of HSA cells in
the GFP population†
% of HSA cells in
the GFP population†
Fold of
inhibition‡
% of HSA cells in
the GFP population†
% of HSA cells in
the GFP population†
Fold of
inhibition‡
A Mock 4.07 NA 4.82 NA
FG12 4.26 5.64 7.26 8.70
lacZ-siRNA 4.16 5.39 7.94 8.33
CCR5-siRNA 2.02 1.48 3.64 5.90 5.76 1.45
B Mock 5.05 NA 6.07 NA
FG12 7.16 7.95 5.15 5.78
lacZ-siRNA 7.98 11.08 7.76 8.15
CCR5-siRNA 2.55 1.73 6.41 6.91 7.41 1.10
NA, not applicable.
*The lentivector-transduced PBLs were challenged with the CCR5- or CXCR4-tropic reporter HIV-1 viruses as described in Fig. 3. Four days after virus challenge,
the cells were analyzed by FACS for HSA expression to determine the number of cells infected by the HIV-1 virus (Materials and Methods).
†Calculated from the quadrant percentage numbers from the HSA vs. GFP FACS plots shown in Fig. 3.
‡Expressed as the ratio of the percentage of HSA cells in the GFP population between lacZ-siRNA and CCR5-siRNA [CCR5-siRNA(186)]-transduced samples.
Table 3. Time course study on the reduction of CCR5 expression
and inhibition to CCR5-tropic HIV-1 infection with the
CCR5-siRNA lentivector-transduced PBLs from different donors
Donor
Days after HIV-1
challenge
Reduction
of CCR5
HIV-1
inhibition
A 4 6.99 3.64
7 6.61 2.64
B 4 9.65 6.41
6 10.54 7.04
8 4.88 5.81
C 4 10.09 1.25
6 8.7 3.48
8 9.56 3.73
D 4 13.26 2.59
6 13.75 3.68
8 5.68 4.09
CD8-depleted PBLs from four different donors were transduced with
various lentiviral vectors, as described in Fig. 2. Four days after the transduc-
tion, the cells were challenged with the CCR5-tropic HIV-1 reporter virus (as in
Fig. 3). The virus-infected cells were analyzed by FACS for CCR5 and HSA
expression at the different time points indicated. The reduction of CCR5
expression and inhibition of CCR5-tropic HIV-1 infection were determined in
the same manner as in Tables 1 and 2. Equivalent degrees of CCR5 down-
regulation were obtained with the similarly transduced cells but not being
challenged with the HIV-1 virus.
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nontransduced cells over the course of HIV-1 infection. As a
control, the lymphocyte populations were also infected with a
CXCR4-tropic HIV-1 reporter virus similarly modified to ex-
press HSA (31). Infection of the CXCR4-tropic virus was not
significantly inhibited by the transduction of an anti-CCR5
siRNA vector (Fig. 3B, Table 2), confirming the specificity of the
siRNA-mediated inhibition. Taken together, we conclude that a
lentivirus vector expressing a potent siRNA against CCR5 can
substantially reduce CCR5 expression on the cell surface in a
specific manner and render the transduced cells relatively resis-
tant to CCR5-tropic HIV-1 infection.
Discussion
These results demonstrate that an siRNA directed to a cellular
gene that is required for HIV-1 infection, namely CCR5, can
inhibit HIV-1 replication. With HIV-1 replication as a model
system, our studies also demonstrate the power and general
utility of using lentiviral vectors for the stable expression of
siRNAs in primary human cells to inhibit the expression of
cellular genes.
The human chemokine receptor gene, CCR5, was chosen as a
target for these studies for several reasons. First, CCR5 is a
necessary coreceptor for infection by most strains of HIV-1 (34,
35). After binding of the HIV-1 envelope protein gp120 to CD4,
interaction with gp120 and CCR5 induces a conformational
change that then leads to HIV-1 envelope gp41 fusion with the
cell membrane (36). This is an obligatory step for the infection
process of CCR5-tropic strains of HIV-1; the absence of CCR5
prevents HIV-1 infection to cells. Not all strains of HIV-1
require CCR5. CXCR4, for example, is another major corecep-
tor (37). However the majority of naturally occurring strains of
HIV-1 use CCR5 as a coreceptor for primary infection (38–41).
Second, CCR5 is apparently dispensable for normal human
growth, differentiation, and immune functions (42). Among the
white population, the occurrence of a CCR5-null allele, known
as CCR532, is1% (21–24). The CCR532 allele is a deletion
resulting in a frameshift truncation of CCR5 that prevents the
mutant protein from appearing on the cell surface (21, 33).
Individuals homozygous for the CCR532 do not show any
apparent adverse phenotypic effects, although a recent report
linked CCR532 homozygosity with higher viral loads in hep-
atitis C infection (43). In heterozygous CCR532 individuals,
cell surface CCR5 is reduced to 20–30% of wild-type levels (33,
44, 45). Again, no adverse effects are observed in these individ-
uals (42). It will be important to confirm that acquired loss of
CCR5 expression through siRNA inhibition also has no adverse
phenotypic effects.
Cohort studies indicate that individuals that are homozygous
for the CCR5 mutation are almost completely resistant to
infection by CCR5-tropic strains of HIV-1 (38–41, 46, 47). To
date, there have been only eight reports of HIV-1 infection in
CCR532 homozygous individuals (48–51). These individuals
appeared to have been infected with a CXCR4-tropic strain of
HIV-1 and did develop AIDS. Individuals that are heterozygous
for CCR532 are infected at rates similar to CCR5CCR5
individuals. However, their disease course is prolonged, presum-
ably because of reduced spread of virus within the individuals
over time (23). Thus, the 3- to 7-fold inhibition produced by our
anti-CCR5 siRNA vector could already have a marked clinical
effect and, with an optimized system, a greater inhibition might
even be obtained. However, it is possible that in a patient
producing HIV-1, anti-CCR5 siRNA could select for viral
variants that use CXCR4 and then cause progression to AIDS.
Therefore, a CCR5 inhibitory therapy would be best used in
combination with other antiviral approaches.
Because of the importance of CCR5 to HIV-1 infection and
disease development, a number of approaches have been inves-
tigated to inhibit the utilization of CCR5 as a coreceptor by
HIV-1. The chemokines, RANTES, MIP-1, and MIP1-, are
physiological ligands for CCR5 and have been shown to inhibit
HIV-1 infection both in vitro and in vivo (52). However, these
chemokines and their pharmacological derivatives have not been
used clinically because they have a short half-life, are not orally
bioavailable, and may have other effects (53, 54). Other inves-
tigators have inhibited CCR5 in vitro by using ‘‘intrakines,’’
fusions of RANTES and MIP1- to endoplasmic reticulum
retention signals (55, 56), and single-chain antibodies directed to
CCR5 (30).
We have shown here that it is possible to obtain at least partial
inhibition of a viral infection by lentiviral vector-mediated
expression of an siRNA targeting a cellular gene. Within the
transduced population of T cells (GFP fraction), we observed
an up to 10-fold inhibition of CCR5 expression. As a conse-
quence, HIV-1 infection within the transduced population was
also substantially reduced, relative to mock-transduced cells,
cells transduced with an irrelevant siRNA (lacZ-siRNA), or
nontransduced cells in the same culture (GFP fraction). How-
ever, there remained transduced cells that were infected by
HIV-1 (HSA). Residual infection of transduced cells may
occur because of incomplete inhibition, variability of inhibition
over time, or infection through a CCR5-independent mechanism
(57). It is important to remember that in this culture system, the
cells are bathed continuously in virus produced by the unpro-
tected cells.
Although a 3-fold reduction of the total virus load in our in
vitro model is rather modest, an effective clinical application of
this technology would be through a hematopoietic stem cell
transplant. In this manner, therapeutic siRNA-expressing stem
cells would give rise to mature progeny T cells, macrophages,
andor dendritic cells that would be relatively protected from
infection by HIV-1. Furthermore, the rapid demise of HIV-1-
infected T cells (58) should lead to rapid selection for the
CCR5-negative cells that are relatively protected from the
effects of HIV-1. We did not observe selection in cell culture,
possibly because the HIV-1 viruses that we used are lacking the
Vpr gene as a result of substitution by the HSA reporter gene.
Vpr induces cell-cycle arrest, followed by apoptosis, which would
lead to rapid selection against HIV-1-infected cells (59). Selec-
tion of transduced cells expressing a therapeutic transgene has
played an important role in the successful human clinical trials
of gene therapy, the treatment of X-linked SCID-X1 and ADA-
SCID genetic disorders (60, 61).
In summary, our studies provide proof of principle for the idea
that siRNA directed to a gene essential for viral replication can
serve as a potential therapeutic agent for human infectious
disease. The utilization of siRNA as a therapeutic reagent in the
clinical setting is advantageous to previously reported ap-
Fig. 4. Decrease of p24 production in HIV-1-infected cultures of anti-CCR5
lentiviral vector-transduced human PBLs. Culture supernatants were collected
6 days after the HIV-1 virus challenge, as described in Fig. 3, and p24 levels were
measured by ELISA in triplicates. Again, the representative result from Donor
B is shown.
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proaches in that siRNA is a small nucleic acid reagent as opposed
to relatively large chimeric or antibody proteins. A small nucleic
acid reagent should be less likely to elicit an immune response.
Furthermore, the relative simplicity of the siRNA approach
lends itself to easy combination with other siRNAs directed to
different regions of CCR5 andor other cellular or HIV-1-
specific genes, which can result in additive or synergistic effects,
and will help to prevent the escape of mutant variants. It seems
possible that further modifications in vector design and choice of
siRNAs simultaneously targeting multiple essential components
for viral replication could provide an effective treatment against
HIV-1.
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